jRCT2041210004已完成不适用
Phase III clinical trial of favipiravir in early-onset COVID-19 patients with severe risk factors -Placebo-controlled, stratified Randomized, Multicenter, Double-blind study -
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 316
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Prevention Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •Patients with positive SARS-CoV-2 test result by RT-PCR or loop-mediated isothermal amplification (LAMP) method or antigen test.
- •Patient within 72 hours from onset of first COVID-19 symptom
- •Patients with risk factors of progression to severe disease
- •Have a negative pregnancy test before study treatment
- •Patients can obtain written informed consent from the patients.
排除标准
- •Patients receiving oxygen therapy prior to the start of study treatment.
- •Patients with any of COVID-19 clinical symptoms/findings of dyspnea or a respiratory rate of 30 breaths/min or more.
- •Patients with SARS-CoV-2 vaccinated
结局指标
主要结局
-
Percentage of patients with severe disease from randomization to Day 28
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
3 期
Phase III clinical trial of favipiravir in early-onset COVID-19 patients with severe risk factorsCOVID-19 patients with risk factors of progression to severe disease onset within 72 hours prior toJPRN-jRCT2041210004Sakurai Tsutomu316
已完成
3 期
Phase III Clinical Study on Favipiravir in Patients with Severe Fever with Thrombocytopenia SyndromeSevere Fever with Thrombocytopenia Syndrome (SFTS)JPRN-jRCT2080223816FUJIFILM Toyama Chemical Co., Ltd. (Former Toyama Chemical Co., Ltd.)30
已完成
3 期
Efficacy and Safety of Favipiravir in Management of COVID-19Coronavirus Disease (COVID-19)NCT04349241Ain Shams University100
进行中（未招募）
1 期
A clinical study of people with HIV-1 who received prior treatment combination of doravirine and islatravirHIV-1 infectionMedDRA version: 20.1Level: LLTClassification code: 10068341Term: HIV-1 infection Class: 10021881CTIS2022-502126-40-00Merck Sharp & Dohme LLC1,312
进行中（未招募）
3 期
Follow-up of Participants Who Received DOR/ISL (100 mg/0.75 mg)HIV-1 InfectionJPRN-jRCT2051230002Tanaka Yoshiyuki1,300